For people living with serious mental illness like schizophrenia or bipolar disorder, standard treatment with antipsychotic medications can be a double-edged sword.
Bristol Myers touts early social and environmental progress among achievements in latest ESG report
A boost for diversity in clinical trials and an earlier-than-expected $1 billion spend with minority-owned businesses are some of the highlights in Bristol Myers Squibb’s